Biosimilar Competition Does Not Reduce Patient Out-of-Pocket Costs for Biologic Drugs
A recent study published in JAMA Health Forum sheds light on the impact of biosimilar competition on patient out-of-pocket (OOP) costs for biologic drugs in the United States. The research,…![](https://www.drugpatentwatch.com/blog/wp-content/plugins/matomo/app/matomo.php?idsite=1&rec=1&url=https%3A%2F%2Fwww.drugpatentwatch.com%2Fblog%2Fbiosimilar-competition-does-not-reduce-patient-out-of-pocket-costs-for-biologic-drugs%2F&action_name=Biosimilar%20Competition%20Does%20Not%20Reduce%20Patient%20Out-of-Pocket%20Costs%20for%20Biologic%20Drugs&urlref=https%3A%2F%2Fwww.drugpatentwatch.com%2Fblog%2Ffeed%2F)